Results of a cohort of 200 hormone-naïve consecutive patients with prostate cancer treated with iodine 125 permanent interstitial brachytherapy by the same multidisciplinary team

Bolla, M.; Verry, Camille; Giraud, Jean-Yves; Long, Jean-Alexandre; Conil, M.; Abidi, R.; Troccaz, Jocelyne; Colonna, Marc; Descotes, Jean‐Luc

doi:10.1016/j.canrad.2014.05.014

Cited by 7 publications

(7 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hormonal blockade, most times prescribed by an urologist previously to the implant, has shown no usefulness as described in other studies like series of the Mount Sinai School of Medicine [ 22 ] or Leeds [ 28 ]. Results of a cohort of 200 hormone-naïve patients had a bRFS of 95.6% at five years [ 29 ], in our study over 97% is achieved without HT, therefore, we consider that it is no longer required except in order to decrease a big prostate volume, over 50-60 cc.…”

Section: Discussionmentioning

confidence: 68%

Comparison of permanent 125 I seeds implants with two different techniques in 500 cases of prostate cancer

Guinot¹,

Ricós

Tortajada³

et al. 2015

jcb

View full text Add to dashboard Cite

PurposeTo perform a comparative study of 500 consecutive 125I seeds implants for intracapsular prostate carcinoma with two techniques differing in terms of both strand implantation and planning.Material and methodsFrom 2002 to 2007 we performed 250 implants with fixed stranded seeds (RapidStrand™) and a preplanning system and from 2007 to 2010, 250 with real-time and ProLink™ system. Mean age was 68 and 66, respectively, median PSA (prostate-specific antigen) 7.3 and 7.2, stage T1-T2a in 98% and 94%, and Gleason ≤ 6 in 96% and 86%. Low risk cases were 81% and 71%. The prescribed dose was 145 Gy to the prostate volume, or 108 Gy plus EBRT 46 Gy in some intermediate risk cases. Hormonal treatment was given to 42% and 28%.ResultsMedian follow-up was 48 and 47 months, respectively, 14 patients in the first group and 7 patients in the second developed biochemical failure (BF). Actuarial biochemical relapse-free survival (bRFS) at 5 years increased from 90.2% to 97.2% (low risk from 91.3% to 97.2%, intermediate risk from 84.2% to 97.1%). Biochemical failure was independent of hormone treatment. Rectal complications were G1-2 in 1.2% and 5.2%, respectively. A urinary catheter was necessary in 6.9% and 9.6%, and urethral resection in 1.9% and 4.4%. Genitourinary toxicity was G1-2 in 4.6% and 12%, G3-4 in 1.9% and 4.8%. An assessment of mean D90 in a sample of patients showed that the dosimetry in postoperative planning based on CT improved from a mean D90 of 143 Gy to 157 Gy.ConclusionsThe outcome of patients with low risk prostate carcinoma treated with 125I seed is very good with low complications rate. The real-time approach in our hands achieved a more precise seed implantation, better dosimetry, and a statistically non-significant better biochemical control. We have made this our standard technique.

show abstract

Section: Discussionmentioning

confidence: 68%

Comparison of permanent 125 I seeds implants with two different techniques in 500 cases of prostate cancer

Guinot¹,

Ricós

Tortajada³

et al. 2015

jcb

View full text Add to dashboard Cite

show abstract

“…Among options of radiotherapy, internal radiotherapy has shown positive results with safety and efficacy [10]. 125 I implantation, one of the internal radiotherapies, has been apply to various kinds of tumors, such as pancreatic carcinoma, lung cancer, prostatic carcinoma, oral and maxillofacial malignancies [24][25][26][27]. Some studies have reported on the application of 125 I seeds to intrahepatic metastases from colorectal adenocarcinoma [28].…”

Section: Discussionmentioning

confidence: 99%

Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3–5cm: A propensity score matching study

Pan

et al. 2016

Digestive and Liver Disease

View full text Add to dashboard Cite

“…Several institutions have reported 5- and 10-year biochemical relapse-free survival ranging from 94-96% [ 2 , 3 , 4 ] to 87-98.5% [ 3 , 5 , 6 , 7 ], respectively. In addition, a number of reviews have demonstrated that LDR brachytherapy is equally effective as EBRT or radical prostatectomy (RP) alone in patients with newly diagnosed low- or intermediate-risk prostate cancer [ 8 , 9 , 10 ]; however, Rodrigues et al .…”

Section: Purposementioning

confidence: 99%

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes

Chao

Spencer

Guerrieri

et al. 2018

jcb

View full text Add to dashboard Cite

PurposeTo report the 5-year biochemical relapse-free survival (BRFS), overall survival (OS), and long-term toxicity outcomes of patients treated with low-dose-rate (LDR) brachytherapy as monotherapy for low- to intermediate-risk prostate cancer.Material and methodsBetween 2004 and 2011, 371 patients were treated with LDR brachytherapy as monotherapy. Of these, 102 patients (27%) underwent transurethral resection of the prostate (TURP) prior to implantation. Follow-up was performed every 3 months for 12 months, then every 6 months over 4 years and included prostate specific antigen evaluation. The biochemical relapse-free survival (BRFS) was defined according to the Phoenix criteria. Acute and late toxicities were documented using the Common Terminology Criteria for Adverse Events version 4.0. The BRFS and OS estimates were calculated using Kaplan-Meier plots. Univariate and multivariate analyses were performed to evaluate outcomes by pre-treatment clinical prognostic factors and radiation dosimetry.ResultsThe median follow-up of all patients was 5.45 years. The 5-year BRFS and OS rates were 95% and 96%, respectively. The BRFS rates for patients with Gleason score (GS) > 7 and GS ≤ 6 were 96% and 91% respectively (p = 0.06). On univariate analysis, T1 and T2 staging, risk-group classification, and prostate volumes had no impact on survival at 5 years (p > 0.1). Late grade 2 and 3 genitourinary (GU) toxicities were observed in 10% and 5% of patients respectively. Additionally, patients with prior TURP had a greater incidence of late grade 2 or 3 urinary retention (p = 0.001). There were 14 deaths in total; however, none were attributed to prostate cancer.ConclusionsLDR brachytherapy is an effective treatment option in low- to intermediate-risk prostate cancer patients. We observed low biochemical relapse rates and minimal GU toxicities several years after treatment in patients with or without TURP. However, a small risk of urinary retention was observed in some patients.

show abstract

Results of a cohort of 200 hormone-naïve consecutive patients with prostate cancer treated with iodine 125 permanent interstitial brachytherapy by the same multidisciplinary team

Cited by 7 publications

References 37 publications

Comparison of permanent 125 I seeds implants with two different techniques in 500 cases of prostate cancer

Comparison of permanent 125 I seeds implants with two different techniques in 500 cases of prostate cancer

Iodine-125 implantation plus transarterial chemoembolization for the treatment of hepatocellular carcinoma of 3–5cm: A propensity score matching study

A single institution analysis of low-dose-rate brachytherapy: 5-year reported survival and late toxicity outcomes

Contact Info

Product

Resources

About